Table 2.
Summary of treatment characteristics.
| Name | Prescription dose (Gy)/fractionation | BED10 (Gy) | Isodose (%) | History of CT | Follow-up of CT | Location of PD | FFLP (months) | PFS (months) | OS (months) | Status (cause) |
|---|---|---|---|---|---|---|---|---|---|---|
| LZJ | 50/5 | 100 | 71 | No CT | Gemcitabine-based | Liver and adrenal gland metastasis | 11.9 | 2.6 | 13.3 | Death (tumor) |
| WBH | 44/4 | 92.4 | 68 | No gemcitabine-based | Gemcitabine-based | Liver metastasis | 12.3 | 6.6 | 12.3 | Death (tumor) |
| LB | 40/5 | 72 | 70 | Gemcitabine-based | No CT | No | 3.6 | 3.6 | 3.6 | Death (gastrointestinal hemorrhage) |
| SXG | 40/4 | 80 | 77 | No CT | No CT | Abdominal wall metastasis | 2.9 | 1.3 | 2.9 | Death (tumor) |
| HXQ | 50/5 | 100 | 75 | Gemcitabine-based | 5-Fu-based | Liver metastasis | 26.3 | 22.6 | 26.3 | Death (tumor) |
| WMH | 42/7 | 67.2 | 76 | Gemcitabine-based | No CT | Liver and lung metastasis | 6.8 | 3.3 | 6.8 | Death (tumor) |
| ZXS | 40/5 | 72 | 75 | Gemcitabine-based | 5-Fu-based | Liver metastasis | 21.8 | 16.7 | 21.8 | Death (tumor) |
| LQB | 40/5 | 72 | 75 | Gemcitabine-based | No CT | No | 3.6 | 3.6 | 3.6 | Death (heart accident) |
| ZQ | 45/5 | 85.5 | 71 | No CT | Gemcitabine-based | Liver metastasis | 13.5 | 10.3 | 13.5 | Death (tumor) |
| WDC | 42/6 | 71.4 | 75 | Gemcitabine-based | 5-Fu-based | Liver and lung metastasis | 30.6 | 27.1 | 30.6 | Death (tumor) |
| ZH | 50/5 | 100 | 75 | Gemcitabine-based | No CT | Treatment site and liver metastasis | 1.3 | 1.3 | 1.3 | Death (tumor) |
| YCH | 40/5 | 72 | 70 | No gemcitabine-based | No CT | Liver metastasis | 8.9 | 7.1 | 8.9 | Death (tumor) |
| WZJ | 42/7 | 67.2 | 81 | Gemcitabine-based | 5-Fu-based | Treatment site | 22.3 | 22.3 | 26.5 | Death (tumor) |
| LYM | 40/5 | 72 | 70 | Gemcitabine-based | 5-Fu-based | Lymphonodus of neck and armpit | 11.3 | 7.6 | 11.3 | Death (tumor) |
| ZL | 40/5 | 72 | 67 | Gemcitabine-based | 5-Fu-based | Liver and retroperitoneal metastasis | 17.7 | 14.2 | 17.7 | Death (tumor) |
| WWJ | 40/5 | 72 | 80 | No CT | 5-Fu-based | Lung metastasis | 15.2 | 9.3 | 15.2 | Death (tumor) |
| GLY | 35/5 | 59.5 | 75 | No CT | No CT | Liver metastasis | 6.9 | 4.3 | 6.9 | Death (tumor) |
| SST | 35/5 | 59.5 | 77 | Gemcitabine-based | No CT | Peritoneum metastasis | 5.3 | 4.1 | 5.3 | Death (tumor) |
| LW | 35/5 | 59.5 | 77 | Gemcitabine-based | 5-Fu-based | Liver metastasis | 6.4 | 2.8 | 6.4 | Death (tumor) |
| XGD | 35/5 | 59.5 | 81 | Gemcitabine-based | Gemcitabine-based | Liver metastasis | 17.1 | 13.6 | 17.1 | Death (tumor) |
| ZJB | 35/5 | 59.5 | 79 | No CT | Gemcitabine-based | Liver and lung metastasis | 15.9 | 14.2 | 15.9 | Death (tumor) |
| CQH | 35/5 | 59.5 | 80 | No CT | Oxaliplatin-based | No | 11.9 | 11.9 | 11.9 | Alive |
| GHL | 35/5 | 59.5 | 77 | No gemcitabine-based | Oxaliplatin-based | No | 11.3 | 11.3 | 11.3 | Alive |
| XZ | 35/5 | 59.5 | 76 | No CT | No CT | Peritoneum metastasis | 7.5 | 5.9 | 7.5 | Death (tumor) |
| WHM | 25/5 | 37.5 | 75 | Gemcitabine-based | 5-Fu-based | No | 9.1 | 9.1 | 9.1 | Alive |
| LAG | 35/5 | 59.5 | 75 | Gemcitabine-based | Irinotecan-based | No | 6.1 | 6.1 | 6.1 | Alive |
| WYZ | 30/5 | 48 | 83 | Gemcitabine-based | Oxaliplatin-based | No | 6.1 | 6.1 | 6.1 | Alive |
Abbreviations: BED, biologically equivalent dose; CT, chemotherapy; PD, progressive disease; FFLP, freedom from local progression; PFS, progression free survival; OS, overall survival time.